syphilis
Biosynex to Acquire Chembio Diagnostics for $17.2M
Biosynex will buy all of Chembio's shares at $.45 per share in an all-cash deal that merges two developers and makers of point-of-care diagnostic tests.
Chembio Diagnostics Receives $3.2M From CDC to Develop Syphilis Test
The rapid assay is intended to simultaneously and separately detect treponemal and nontreponemal IgM and IgG antibodies.
In recent CDC data, racial and sexual orientation minorities, especially, have been disproportionately affected by STDs.
MedMira Obtains CE Marking for Antibody-Based Syphilis Test, Plans Canadian Clinical Trials
The syphilis rapid test, which detects Treponema pallidum antibodies, will be made available for testing at the point of care in countries that accept the CE mark.
Chembio Diagnostics Q1 Revenues Climb 26 Percent on Government Grant Income
The firm said that in Q1 its product revenues fell 30 percent year over year to $4.0 million, but government grant income contributed $3.4 million to its revenues.
Mar 12, 2021
Aug 16, 2018
STD Testing Firm MyLab Box Raises $1.56M
May 9, 2018
Chembio Q1 Revenues Rise 22 Percent
Mar 8, 2018
Chembio Q4 Revenues Grow 40 Percent
Jun 12, 2017
Bio-Rad Gets FDA Clearance for Syphilis Assay
May 10, 2017
Chembio Diagnostics' Q1 Revenues Drop 5 Percent
Mar 8, 2017
ChemBio Q4 Revenues Decline 2 Percent
Jan 17, 2017